摘要
类癌综合征(carcinoid syndrome,CS)是由神经内分泌肿瘤分泌的血管活性物质引发,以皮肤潮红、腹泻、腹痛及类癌性心脏病(carcinoid heart disease,CHD)为典型表现的临床综合征。随着诊断技术进步,CS临床诊断率显著上升,但系统性流行病学数据仍不足。当前CS的诊治领域面临标准缺失、症状非特异性及疗效差异等挑战,诊断需结合24 h尿5-羟基吲哚乙酸检测、影像学评估及临床症状;治疗以个体化策略为核心,包括生长抑素类似物、内镜治疗、外科治疗、介入治疗、药物治疗、放疗、肽受体放射性核素治疗、肝脏定向治疗等多种手段。整个诊治过程均需多学科协作,涵盖CHD和类癌危象的管理。《类癌综合征诊治中国专家共识》提出标准化诊疗路径,以规范临床实践,提升患者生存质量。
Carcinoid syndrome(CS)is a clinical syndrome triggered by vasoactive substances secreted from neuroendocrine neoplasms,characterized by flushing,diarrhea,abdominal pain,and carcinoid heart disease(CHD).Advances in diagnostic techniques have increased clinical recognition of CS,yet systematic epidemiological data remain limited.Current challenges include the absence of standardized guidelines,non-specific symptoms,and variable treatment efficacy.Diagnosis integrates 24-hour urinary 5-hydroxyindoleacetic acid testing,imaging,and clinical evaluation.Treatment focuses on personalized approaches,including somatostatin analogue,endoscopic therapy,surgical treatment,interventional therapy,drug therapy,radiation therapy,peptide receptor radionuclide therapy,and liver-directed interventions.Multidisciplinary collaboration is critical throughout the entire diagnostic and therapeutic process,encompassing the management of CHD and carcinoid crisis.This consensus establishes standardized protocols to optimize clinical practice and improve patient outcomes.
出处
《肿瘤综合治疗电子杂志》
2025年第6期1-14,共14页
Journal of Multidisciplinary Cancer Management(Electronic Version)
